Category: Blog

Your blog category

  • Paragon 28 Adds Second Mobile Medical Education Lab, Significantly Expanding Hugely Successful Training Program for Foot and Ankle Surgeons

    Paragon 28 Adds Second Mobile Medical Education Lab, Significantly Expanding Hugely Successful Training Program for Foot and Ankle Surgeons

     

    ENGLEWOOD, CO, November 13, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile laboratory training program, making it even easier for the company to facilitate on-site training and education of surgeons. Paragon 28’s new mobile laboratory is housed in a 40-foot tractor-trailer with a state-of-the-art cadaver training facility with 5 stations and space for up to 25 surgeons. The mobile laboratory will host more than 70 training sessions in approximately 65 U.S. cities in the fourth quarter of 2023. The mobile laboratory program launched in July 2022 and has been an incredible success for Paragon 28, allowing the company to efficiently train more than 350 surgeons.

    “We are very excited to add a second laboratory to our mobile education program and increase our ability to bring education directly to surgeons. The mobile laboratory program has enabled Paragon 28 to find the most effective location for medical education to support our growing product portfolio and surgeon customers,” said Albert DaCosta, CEO and co-founder of Paragon 28. “The mobile laboratory program has proven to be an effective and versatile option to showcase P28’s broad and innovative product portfolio, which includes new solutions in the growing forefoot, HAV and rearfoot market segments.”

    For more information about the Paragon 28 Surgeon Mobile Lab, visit the following site: Paragon 28 Mobile Lab

    About Paragon 28, Inc.

    Based in Englewood, CO., Paragon 28 is a leading medical device company focused exclusively on the foot and ankle orthopedic market and committed to improving the lives of patients. Since its inception, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and devices covering a wide range of foot and ankle conditions, including fracture fixation, hallux valgus (bunions), hammer toe, ankle, progressive collapsible foot deformity (PCFD) or flat foot, Charcot foot and orthobiology. The company designs products with both the patient and surgeon in mind, with the goals of improving outcomes, reducing recurrences of disease and complications, and making procedures simpler, more consistent and reproducible.

    Forward-Looking Statements

    Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to to: Paragon 28’s potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates and assumptions, which speak only as of the date on which they are made, and are subject to risks and uncertainties, some of which we are not currently aware of. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at or at which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with Paragon 28’s business generally, see the current and future reports from Paragon 28 filed with the Securities and Exchange Commission. Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements . except as required by law.

    Contacts

    Contact person for investors

    Matthew Brinckman
    Senior Vice President, Strategy and Investor Relations
    Phone: (720) 912-1332
    mbrinckman@paragon28.com

    Image: Business Wire

    Source link

  • One in five people taking nirmatrelvir-ritonavir treatment were found to experience rebound COVID

    One in five people taking nirmatrelvir-ritonavir treatment were found to experience rebound COVID

    Arthritis

    A new study by researchers at Mass General Brigham found that one in five people taking Nirmatrelvir-ritonavir treatment, commonly known as Paxlovid, to treat severe symptoms of COVID-19 experienced a positive test result and excretion of live and potentially contagious virus after initial recovery and negative test; a phenomenon known as virological rebound. In contrast, people who didn’t take Paxlovid experienced a rebound only about 2 percent of the time. Results are published in Annals of Internal Medicine.

    We conducted this study to answer lingering questions about Paxlovid and virologic rebound in the treatment of COVID-19. We found that the virological rebound phenomenon was much more common than expected – in more than 20% of people taking Paxlovid – and that individuals shed live virus when they experience a rebound, indicating the potential for transmission after initially recovering were from the virus.”

    Mark Siedner, MD, MPH, Corresponding author, physician and infectious disease researcher at the Division of Infectious Diseases at Massachusetts General Hospital

    Paxlovid is an oral antiviral medication used to treat COVID-19. Previous studies show the drug’s effectiveness in reducing hospitalizations and deaths in cases of severe COVID-19 infection. Since the integration of Paxlovid into the treatment of COVID-19, some patients have reported a virological rebound. A previously conducted phase 3 clinical trial, known as EPIC-HR, suggested that only 1% to 2% of patients taking Paxlovid experienced a virological rebound. However, research by Siedner and colleagues shows that this phenomenon is much more common than previously suspected.

    Paxlovid remains a life-saving drug that I prescribe to high-risk patients. This study, while informative, does not change the fact that this drug is highly effective in preventing hospitalizations and death. Instead, it provides valuable insights to Paxlovid patients, helping them understand what to expect and how long they may remain contagious.”

    Jonathon Li, MD, co-senior author, infectious disease physician and investigator in the Division of Infectious Diseases at Brigham and Women’s Hospital

    Siedner, Li, and other researchers from Mass General Brigham collected data from the Post-vaccination Viral Characteristics Study (POSITIVES), an ongoing study of individuals diagnosed with acute COVID-19 infections. Between March 2022 and May 2023, 142 individuals were selected for the study based on positive COVID-19 tests, medication prescriptions or physician referrals. Sorting participants into those who followed a five-day Paxlovid regimen and those who did not, they closely monitored patients’ viral loads and symptoms, cultured virus samples and performed whole genome sequencing. Patients who tested positive for COVID-19 after previously testing negative and those who showed two consecutive increases in viral load after an initial reduction were classified as having virological rebound.

    Researchers found that 20.8% of participants taking Paxlovid experienced a virological rebound, while only 1.8% of those not taking Paxlovid had a similar rebound effect. Those with a rebound also showed prolonged virus shedding – an average of 14 days compared to less than 5 days in those who did not experience a rebound – suggesting they were potentially contagious for much longer. Importantly, Siedner’s team found no evidence of drug resistance in these patients.

    The findings should not deter doctors from prescribing the medication, the researchers noted, but they should prompt them to counsel patients taking the medication about the risk of viral rebound and spreading the virus to others. Advising patients to retest and isolate in case of a rebound should be part of that conversation, the team said.

    The original EPIC-HR study assessed patient outcomes at only two time points. When the Mass General Brigham researchers matched their data analysis to selected time points from the EPIC-HR study, they found virologic recovery in only 2.4% of participants, suggesting that the previous study did not capture the full extent of represented virological recovery.

    “In our study, we were able to closely monitor patients from the onset of COVID-19 infection through treatment and rebound,” Li explains. “Unlike the EPIC-HR study, which assessed outcomes at only two time points, we followed up with patients three times a week, sometimes for months, and performed sample collection at home. We also had both viral RNA levels as viral culture data. have allowed us to paint a more comprehensive and nuanced picture of a patient’s experience with Paxlovid.”

    This study is limited in that it was an observational study and not a randomized, controlled trial. Thus, the authors cannot be certain that the increased rebound rate observed in people taking Paxlovid was solely due to use of the drug. The team used a positive virus culture as a measure of risk of transmitting the virus, but could not formally measure how contagious someone was who experienced a virological rebound. Furthermore, the team could not explain why some people experienced a rebound and others did not. something they want to explore with future studies. They also plan to investigate the biological mechanism behind the rebound phenomenon associated with Paxlovid and determine whether changing the duration of treatment can help combat this rebound effect.

    Source:

    Magazine reference:

    Edelstein, G.E. et al. (2023) SARS-CoV-2 virological rebound with nirmatrelvir-ritonavir therapy. Annals of Internal Medicine. doi.org/10.7326/M23-1756.

    Source link

  • Substitute Surgical Reports Third Quarter 2023 Financial Results

    Substitute Surgical Reports Third Quarter 2023 Financial Results

     

    WALTHAM, Mass., November 13, 2023–(BUSINESS WIRE)–Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company committed to improving patient outcomes, as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended September 30, 2023. Management will host a corresponding conference call today, November 13, 2023, at 4:30 PM ET.

    “The third quarter brought several successes for our company, but also introduced new challenges as we focused on building and integrating our version 1.0 system,” said Adam Sachs, co-founder and Chief Executive Officer. “While we were pleased with our ability to expand our cash runway through a follow-on equity offering and make meaningful progress on our individual subsystem builds, the impact of recent market-driven cost savings initiatives coupled with certain integration challenges has forced us to adjust our development schedule revised. We now expect to complete build and integration of the Version 1.0 system in Fall 2024 and therefore anticipate a De Novo submission around early to mid 2026. While there is still work to be done, we remain confident that our differentiated technology will allow us to revolutionize surgical robotics and transform the standard of care.”

    Financial results third quarter 2023

    • Operating expenses were $21.4 million for the third quarter of 2023, compared to $22.2 million in the corresponding period last year, a decrease of 4%.
    • R&D expenditures for the third quarter of 2023 were $13.0 million, compared to $12.1 million in the third quarter of 2022.
    • General and administrative expenses for the third quarter of 2023 were $6.9 million, compared to $8.1 million in the third quarter of 2022.
    • Sales and marketing expenses for the third quarter of 2023 were $1.4 million, compared to $1.9 million in the third quarter of 2022.
    • GAAP net loss for the third quarter was $15.7 million, representing a net loss per share of $0.10, compared to a GAAP net loss of $24.7 million, representing a net loss per share of $0.20 for the same period of the previous year. Adjusted net loss for the third quarter was $20.4 million, representing a net loss of $0.12 per share, compared to an adjusted net loss of $21.7 million, or a net loss of $0.18 per share, for the same period of the previous year.
    • The company had $110 million in cash, cash equivalents and short-term investments as of September 30, 2023, including $47 million in gross proceeds from the August follow-on equity offering. Excluding these gross revenues, cash burn for the third quarter of 2023 was $16.8 million.
    • The company reduced fiscal 2023 cash burn guidance to $60-$65 million and initiated a preliminary fiscal 2024 cash burn guidance of $40-$55 million.

    Conference call

    Vicarious Surgical will hold a conference call to discuss its third quarter 2023 financial results on Monday, November 13, 2023 at 4:30 PM ET. Investors wishing to listen to the conference call can do so by dialing +1 (404) 975 4839 for domestic callers or +1 (929) 526 1599 for international callers and using the access code: 083118. A live and archived webcast of the event will be available at https://investor.vicarioussurgical.com.

    About vicarious surgery

    Founded in 2014, Vicarious Surgical is a next-generation robotics company developing a unique disruptive technology with multiple objectives: significantly increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. The company’s new surgical approach uses patented humanoid surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The company is headquartered in Waltham, Massachusetts. More information can be found at www.vicarioussurgical.com.

    Use of Non-GAAP Financial Measures

    In addition to providing financial measures prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), Vicarious Surgical provides additional financial measures not prepared in accordance with US GAAP (“non-GAAP ”). ”). The non-GAAP financial measures included in this press release are adjusted net loss and adjusted net loss per share (“adjusted earnings per share,” and together with adjusted net loss “non-GAAP financial measures”). The company presents non-GAAP financial measures to help readers of its consolidated financial statements understand key operating results that management uses to evaluate the business and for financial planning purposes. Vicarious Surgical’s non-GAAP financial measures provide investors with an additional tool to compare financial performance over multiple periods.

    Adjusted net loss and adjusted earnings per share are key performance measures that Vicarious Surgical management uses to assess operating performance. These non-GAAP financial measures facilitate internal comparisons of Vicarious Surgical’s operating performance on a more consistent basis. Vicarious Surgical uses these performance measures for business planning purposes and forecasting. Vicarious Surgical believes that the non-GAAP financial measures enhance an investor’s understanding of Vicarious Surgical’s financial performance as it is useful in assessing its operating performance from period to period by excluding certain items from which Vicarious Surgical believes they are not representative of its core business. .

    The non-GAAP financial measures may not be comparable to similar measures of other companies because they may not calculate this measure in the same way. Adjusted net loss and adjusted earnings per share are not prepared in accordance with US GAAP and should not be considered separately from, or as an alternative to, measures prepared in accordance with US GAAP. When evaluating Vicarious Surgical’s performance, you should consider its non-GAAP financial measures in addition to other financial performance measures prepared in accordance with US GAAP, including net loss.

    The non-GAAP financial measures do not replace the presentation of Vicarious Surgical’s financial results in accordance with US GAAP and should only be used in addition to, and not as a substitute for, Vicarious Surgical’s financial results presented in accordance with US GAAP. In this press release, Vicarious Surgical has provided a reconciliation between adjusted net loss and net loss, the most directly comparable financial measure under US GAAP, and the adjusted earnings per share calculation.

    Forward-Looking Statements

    This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from expectations, estimates and projections and, accordingly, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact contained herein, including but not limited to quotes from our Chief Executive Officer regarding, among other things, Vicarious Surgical’s opportunities, are forward-looking statements that reflect management’s current beliefs and expectations. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are beyond Vicarious Surgical’s control and are difficult to predict. Factors that could cause such differences include, but are not limited to: changes in applicable laws or regulations; Vicarious Surgical’s ability to obtain future financing; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential features and benefits of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious System within the expected timeline, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for replacement surgery; Vicarious Surgical’s ability to identify, license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing licensing, manufacturing, supply and distribution agreements and scale production of the Vicarious Surgical System and any future product candidates to commercial quantities; Vicarious Surgical’s ability to compete with other companies that currently market or engage in products and services that Vicarious Surgical currently markets or develops, as well as the use of open operations; the size and growth potential of the markets for Vicarious Surgical’s product candidates and services, and its ability to serve those markets, alone or in collaboration with others; the pricing of Vicarious Surgical’s product candidates and services and reimbursement for medical procedures performed using the product candidates and services; the company’s ability to meet its estimates regarding expenses, revenues, capital requirements, cash runway and additional financing needs; Vicarious Surgical’s financial performance; Vicarious Surgical’s intellectual property rights, its ability to protect or enforce those rights, and the impact on its business, results of operations and financial condition if it fails to do so; economic downturn, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; the impact of COVID-19 on Vicarious Surgical’s operations; and other risks and uncertainties identified from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Vicarious Surgical disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

    SEE FINANCES HERE

    Source link

  • Fried mushrooms |  GF |  BoneCoach™ Recipes – BoneCoach™

    Fried mushrooms | GF | BoneCoach™ Recipes – BoneCoach™

     

    Ready to elevate your basic mushroom recipe into a memorable, melt-in-your-mouth side dish?

    This sautéed mushroom recipe makes a wonderful accompaniment that goes with a variety of main dishes.

    Moreover, mushrooms are not only delicious, but they are also a source of important nutrients such as protein, fiber, vitamin D and selenium, which are important for bone health.

    Combine it with your favorite source of organic protein and you have a simple, flavorful dinner.

    Enjoy your meal!

    Bone Coach Recipes | Fried mushrooms | Bone loss Bone Healthy diet Nutrients Osteoporosis

    SERVES: 2

    TOTAL TIME: 10 minutes

    Ingredients

    1 tablespoon (15 ml) ghee or freshly pressed extra virgin olive oil

    225 g mushrooms

    1 shallot, finely chopped

    1/4 teaspoon (1 ml) sea salt

    1 clove garlic, minced

    2 teaspoons (10 ml) fresh thyme (or 1/2 teaspoon dried thyme)

    Directions

    1) Heat a frying pan over medium heat. Once hot, add the ghee, mushrooms and shallot. Fry for 2 minutes and then add the salt. Continue cooking for 5 minutes, stirring frequently.

    2) Add the garlic and thyme and cook for another minute until the garlic is fragrant. Remove from heat and enjoy immediately!

    Recipe created by BoneCoach™ Team Dietitian Amanda Natividad-Li, RD & Chef.

    Medical disclaimer

    The information shared above is for informational purposes only and is not intended as medical or nutritional therapy advice; it does not diagnose, treat or cure any disease or condition; it should not be used as a substitute or substitute for medical advice from physicians and trained medical professionals. If you are under the care of a healthcare professional or are currently taking prescription medications, you should discuss any changes in your diet and lifestyle or possible use of nutritional supplements with your doctor. You should not stop prescribed medications without first consulting your doctor.

    Source link

  • Hospital for Special Surgery and NCH Break Ground on New Orthopedics Center of Excellence in Southwest Florida

    Hospital for Special Surgery and NCH Break Ground on New Orthopedics Center of Excellence in Southwest Florida

     

    NAPLES, Fla., Nov. 13, 2023 /PRNewswire/ — Hospital for Special Surgery (HSS) and NCH today officially broke ground on the Patty & Jay Baker Pavilion, marking the beginning of construction on the new HSS at NCH musculoskeletal ( MSK) center. Located on the campus of NCH North Naples Hospital, the center promises to provide unparalleled orthopedic care to Naples and Southwest Florida.

    Today’s ceremony marks the start of construction that will result in a state-of-the-art facility on the NCH North Naples Hospital campus spanning more than 80,000 square feet. The center will offer outpatient and inpatient orthopedic services, including an ambulatory surgery center and imaging and rehabilitation services that will be jointly owned and managed with HSS. With the aim of funding this project primarily through private philanthropy, the new facility is expected to open to patients in early 2025.

    “I am extremely proud to have helped bring HSS to our community,” said Jay Baker, Board Trustee at NCH, who, along with his wife Patty, committed a $20 million match grant intended for orthopedic services. “The new partnership with HSS at NCH is a testament to our commitment to world-class healthcare, and we are honored to have contributed to this transformative endeavor.”

    Founded in 1863 and headquartered in New York City, HSS is the world’s leading academic medical center specializing in musculoskeletal health. HSS has been recognized as one of the top-rated hospitals in both orthopedics and rheumatology for 31 years in a row. 1 in orthopedics worldwide for the past four years by Newsweek and nationally since 2010 by US News & World Report. They perform more than 35,000 orthopedic surgical procedures annually and consistently maintain the lowest complication and readmission rates for orthopedics in the country.

    Last summer, HSS and NCH proudly announced the appointment of HSS renowned orthopedic trauma surgeon David L. Helfet, MD, as HSS Executive Medical Director at NCH. Although Dr. Helfet’s focus on orthopedic trauma has gained international recognition, he also specializes in hip disorders and is part of the Hip Preservation Service at HSS. He is consistently ranked as one of New York Magazine’s “Best Doctors in New York” and Castle Connolly’s “America’s Top Doctors.” Under the leadership of Dr. Helfet, HSS at NCH will bring expert orthopedic surgeons to the area to perform a wide range of state-of-the-art orthopedic procedures.

    Thousands of Florida residents are among the patients from more than 100 countries and all 50 states who have visited New York City for treatment at the HSS main campus. With the groundbreaking development of the HSS at the NCH Center, these partners are one step closer to realizing their vision of bringing leading orthopedic care to the community without having to travel outside of Southwest Florida.

    “This groundbreaking marks an important milestone in our quest to bring world-class orthopedic care to our community as NCH continues its journey to become an Advanced Community Healthcare System™,” said Paul Hiltz, President & CEO of NCH. “We are pleased to partner with HSS – the world leader in orthopedics – to make this high level of care available to our patients.”

    “NCH and HSS are both patient-centered organizations committed to high-quality care, and we are aligned in our goal of making the highest quality orthopedic care more accessible to the people of Southwest Florida,” said Bryan T. Kelly, MD , MBA. “This is especially important to us at HSS, where we feel a great sense of responsibility not only to help more people, but also to consistently achieve the highest quality outcomes for patients.”

    “This new center, made possible by Patty and Jay Baker, will ultimately shape the way world-class orthopedic care is delivered to this community for generations to come,” said Dr. Helfet. “We are building a world-class team of physicians, surgeons, nurses and more, from around the world and within this community.”

    “Our growing team is already hard at work transferring and implementing HSS knowledge, standards and methods to achieve the highest quality clinical care and patient experience in the world right here in Southwest Florida,” added Dr. Helfet.

    All donations to support orthopedic services at NCH will be matched by the $20 million grant pledged by the Bakers. For more information about how you can support HSS at NCH and become part of this historic partnership, please contact the NCH Center for Philanthropy at 239-624-2000.

    About NCH

    NCH ​​​​is a locally governed nonprofit organization and Advanced Community Health System™ based in Naples, Florida. The system consists of more than just two hospitals (called NCH Baker Hospital and NCH North Hospital) with a total of 713 beds. NCH ​​​​is an alliance of 775 physicians and medical facilities in dozens of locations throughout Southwest Florida that provides nationally recognized, high-quality health care to our community. Our mission is to help everyone live longer, happier and healthier lives. For more information, visit www.NCHmd.org.

    About HSS

    HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is the Hospital for Special Surgery, ranked #1 nationally in orthopedics (for the 14th year in a row), #2 in rheumatology by US News & World Report (2023-2024), and the top pediatric orthopedic hospital in New York. NJ and CT by US News & World Report “Best Children’s Hospitals” list (2023-2024). In a survey of medical professionals in more than twenty countries by Newsweek, HSS ranks first in the world in orthopedics for the fourth year in a row (2024). Founded in 1863, the hospital has the lowest readmission rates in the nation for orthopedics, and one of the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. HSS, an affiliate of Weill Cornell Medical College, has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as on the east coast of Florida. In addition to patient care, HSS is a leader in research, innovation and education. The HSS Research Institute consists of 20 laboratories and 300 employees focused on leading the advancement of musculoskeletal health through the prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute works to realize the potential of new medicines, therapies and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, paramedics, academic trainees and consumers in more than 165 countries. The institution collaborates with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. http://www.hss.edu.

    SOURCE Hospital for Special Surgery

    Source link

  • 2024-2025 – Rush Research Fellowship – Orthopedic Oncology

     

    Prerequisites for the position include:

    – Ability to start on campus within the recommended time frame

    – Successful completion of the third year before start date

    – Strong motivation for a career in orthopedic surgery

    – Clear interest in research and a strong academic record

    – MUST be extremely organized and detailed

    – MUST have strong communication skills

    – MUST be able to work self-directed and independently

    – MUST be able to work efficiently with clinical staff and a multidisciplinary team

    – Experience with statistical analysis and/or coding is highly recommended

    Fellowship responsibilities include:

    – Coordination of all (30+) research projects of the principal investigator, including both clinical and basic science studies.

    – Maintaining weekly surgical case logs and enrolling patients in the research database.

    – Drawing up/delivering/updating protocols within the IRB.

    – Participate in biweekly research meetings with Dr. Blank, as well as weekly resident education and multidisciplinary Sarcoma conferences.

    – Presentation of weekly project updates at the above-mentioned conferences.

    – Data entry into EMR platforms and uploading procedural documents to electronic platforms.

    – Collection of intraoperative data and follow-up of patients in the clinic and/or by telephone.

    – Analysis of data from internal or national databases using statistical software (can access SPSS and STATA).

    – Drafting/editing/producing manuscripts, abstracts and book chapters on orthopedic oncology/orthopedic surgery, along with preparing posters/presentations for conferences.

    – Interface and coordination of projects with attendees, fellows, residents and students.

    Benefits of the position:

    – The fellow can expect to have more than 10 papers/abstracts/presentations accepted or already published by the end of the research year.

    – Improve competitiveness for a residency position in orthopedic surgery. This will be the second year of this position.

    – Opportunities to collaborate with tumor researchers, orthopedic residents and other Rush employees.

    – Opportunities to observe surgical procedures and master orthopedic assessments in the clinic.

    – Opportunities to attend orthopedic grand rounds, tumor conferences, journal clubs and cadaver laboratories

    – Opportunities to present research at national conferences on orthopedic surgery and oncology.

    -Dr. Blank fully expects that his research colleague will make a match in the field of Orthopedic Surgery at one of their preferred programs and assist the candidate during the matching process.

    Interested applicants should send the following items to our research team at: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Subject: Research grant – Last name, first name

    Starting date

    A short motivation letter describing your interest

    An essay of less than 200 words outlining the interest in Rush

    Resume with USMLE Step 1 score (and Step 2 scores, if available)

    Internal medicine and surgery shelf scores (if available)

    The application deadline is January 30, 2024. Applicants will be contacted shortly afterwards for a video interview.

    Thank you for your interest in this position.

    Source link

  • Food allergies may be linked to an increased risk of cardiovascular disease, research shows

    Food allergies may be linked to an increased risk of cardiovascular disease, research shows

     

    Sensitivity to common food allergens such as dairy and peanuts could be a major and previously unappreciated cause of heart disease, new research suggests – and the increased risk of cardiovascular disease extends to people without obvious food allergies.

    Food allergies may be linked to an increased risk of cardiovascular disease, research shows
    Dairy and common foods like peanuts may be a major and previously underappreciated cause of heart disease, new research suggests – and the increased risk of cardiovascular disease includes even people without apparent food allergies. Image credits: UVA Health

    That increased risk could equal or even exceed the risks of smoking, diabetes and rheumatoid arthritis, the researchers report.

    UVA Health scientists and their collaborators looked at thousands of adults over time and found that people who produced antibodies in response to dairy and other foods were at increased risk for cardiovascular disease. This was true even when traditional risk factors for heart disease, such as smoking, high blood pressure and diabetes, were taken into account. The strongest association was for cow’s milk, but other allergens such as peanuts and shrimp were also significant.

    The disturbing finding represents the first time that ‘IgE’ antibodies against common foods have been linked to an increased risk of cardiovascular death, the researchers report. The findings do not conclusively prove that food antibodies cause the increased risk, but the work builds on previous studies that linked allergic inflammation and heart disease.

    About 15% of adults produce IgE antibodies in response to cow’s milk, peanuts and other foods. Although these antibodies cause some people to develop severe food allergies, many adults who produce these antibodies do not have an overt food allergy. The new research found that the strongest link with cardiovascular death was in people who had the antibodies but continued to consume the food regularly – suggesting they did not have a severe food allergy.

    “What we were looking at here was the presence of IgE antibodies to food that were detected in blood samples,” says researcher Jeffrey Wilson, MD, PhD, an allergy and immunology expert at the University of Virginia School of Medicine. “We don’t think most of these subjects actually had a food allergy. So our story is more about an otherwise silent immune response to food. While these reactions may not be strong enough to cause acute allergic reactions to food, they can still cause inflammation and over time lead to problems such as heart disease.”

    Unexpected findings about food allergy

    The researchers were inspired to explore the possibility that common food allergies could harm the heart after members of the UVA team previously linked an unusual form of food allergy, spread by ticks, to heart disease. That allergy, first identified by Thomas Platts-Mills, MD, PhD of UVA, is transmitted by the bite of the lone star tick, found across much of the country.

    The allergy – commonly incorrectly called the ‘red meat allergy’ – makes people sensitive to a certain sugar, alpha-gal, found in mammalian meat. The symptomatic form of the allergy, known as “alphagal syndrome,” can cause hives, stomach upset and breathing difficulties – even potentially fatal anaphylaxis – three to eight hours after affected people eat beef or pork. (Poultry and fish don’t contain the sugar, so won’t cause a reaction.)

    To see whether other food allergies might affect the heart, a team including Wilson, Platts-Mills and collaborators at UVA, as well as Corinne Keet, MD, PhD, of the University of North Carolina, reviewed data collected from 5,374 participants in the National Health and Examination Survey (NHANES) and the Wake Forest site of the Multi-Ethnic Study of Atherosclerosis (MESA). Of those people, 285 had died from cardiovascular causes.

    Among NHANES participants, IgE antibodies against at least one food were associated with a significantly higher risk of cardiovascular death, the researchers found. This was especially true for people who are sensitive to milk, a finding that also held true among the MESA participants. Additional analysis also identified peanut and shrimp sensitization as significant risk factors for cardiovascular death in individuals who ate them routinely.

    “We previously noted a link between allergic antibodies to the alpha-gal red meat allergen and heart disease,” Wilson explained. “That finding is supported by a larger study in Australia, but the current paper suggests that a link between allergic antibodies to food allergens and heart disease is not limited to alpha-gal. In some ways this is a surprising finding. On the other hand, we are not aware of anyone having looked before.”

    Allergies and the heart

    Although this is the first time that allergic antibodies to common foods have been linked to cardiovascular death, other allergic conditions – such as asthma and the itchy rash known as eczema or atopic dermatitis – have previously been identified as risk factors for cardiovascular disease.

    The researchers speculate that allergic antibodies to food may affect the heart by leading to the activation of specialized cells called mast cells. Mast cells in the skin and intestines are known to contribute to classic allergic reactions, but they are also found in cardiac blood vessels and tissue. Continued activation of mast cells can cause inflammation, contributing to the formation of harmful plaques that can cause heart attacks or other heart damage, the researchers think.

    However, the scientists emphasize that this is not yet certain. It is possible that other genetic or environmental factors play a role. It’s even possible that cardiovascular disease could increase the risk of food sensitization – meaning heart disease could increase the risk of food allergies, rather than the other way around – although the new results suggest this is unlikely.

    The researchers call for further research to better understand the implications of their findings before recommending changes in the way doctors treat or manage food allergies.

    This work raises the possibility that a blood test could help provide personalized information about a heart-healthy diet in the future. Although before that can be recommended, we still have a lot of work to do to understand these findings.”

    Jeffrey Wilson, allergy and immunology expert, University of Virginia School of Medicine

    Findings published

    The researchers published their findings in the leading allergy journal, the Journal of Allergy and Clinical Immunology. The research team consisted of Keet, Emily McGowan, David Jacobs, Wendy Post, Nathan Richards, Lisa Workman, Platts-Mills, Ani Manichaikul and Wilson. Wilson and Platts-Mills have received support from Thermo-Fisher/Phadia; a full list of the authors’ disclosures is included in the article.

    The research was supported by the National Institute of Allergy and Infectious Disease of the National Institutes of Health under grants 5U01AI125290, R37-AI20565, and R21AI151497; and by an AAAAI Foundation Faculty Development Award. A list of the funders of the MESA trial is available in the paper.

    Source:

    University of Virginia Health System

    Magazine reference:

    Keet, C., et al. (2023) IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Journal of Allergy and Clinical Immunology. doi.org/10.1016/j.jaci.2023.09.038.

    Source link

  • Spine Research Fellowship – Gillette Children’s Hospital (2024-2025)

     

    The Gillette Children’s Hospital Pediatric Orthopedic Research Fellowship is a fully funded, one-year fellowship program intended for medical students and recent medical school graduates who are interested in pursuing a career in orthopedic surgery. Fellows will participate in clinically informed pediatric orthopedic research and gain experience in all facets of research activities, including design, implementation and dissemination. In addition to actively participating in research, fellows will have the opportunity to attend daily didactic educational sessions in the Department of Pediatric Orthopedic Surgery, observe the clinical and surgical management of children with complex spine conditions, and receive mentorship from our clinical and research team.

    To be considered for this opportunity, please submit your CV, transcript (can be unofficial) and motivation letter with your application with the points below:

      1. Experience with research, scientific writing and/or literature research.

     

      1. Your goals and expectations for this one-year research fellowship at Gillette Children’s.

     

      1. How this one-year research grant can help you realize your ultimate career plans in medicine.

     

    compensation and benefits

    The hourly rate for this opportunity is $22/hour. Hourly wages are only part of the employee compensation package. Gillette supports career development and offers a competitive benefits package, including a retirement savings plan, tuition and degree reimbursement, paid time off and health and wellness benefits.

    Significant challenges

      • Make significant contributions to multiple research projects, including designing the research protocol, obtaining human subject approvals, collaboration and communication among the research team, and involvement in data analysis.

     

      • Lead dissemination efforts, resulting in submission of abstracts for presentation at a scientific conference and/or submission of peer-reviewed manuscripts for publication.

     

      • Manage timelines for ongoing projects while maintaining a weekly schedule consisting of team conferences, clinics, and mentorship meetings.

     

      • Meet internal and external deadlines to ensure consistent progress on ongoing projects, including research activities, presentations, manuscripts, grant proposal development, and other collaborative work.

     

    Key Job Responsibilities

    The fellow will be involved in a variety of research projects designed to answer questions and solve problems in pediatric spine, patient safety, and healthcare quality and value, as well as medical economics. Completed projects will be submitted for publication in high-quality journals and presentations at regional, national and international conferences.

    Qualifications

    Required (for Fellowship start date on or about July 1, 2024):

      • Fellows have completed their third year of medical school. Exceptional candidates who have completed their second year of medical school are also eligible.

     

      • Fellows are in good academic standing and have an interest in pursuing a career in orthopedics or spine surgery.

     

    Preference:

      • Fellows have previous experience in scholarly writing, literature review, and/or research experience.

     

    Gillette Children’s is committed to recruiting and retaining a diverse team because we know that the diverse experiences of our employees make Gillette a stronger and better organization. We strive to create an equitable and inclusive environment where all patients, families and staff are welcomed and valued. We believe that diverse perspectives and identities promote excellence, improve patient care and are essential for Gillette to fulfill its mission. Our team members work together to help patients of all backgrounds and abilities reach their full potential.

    Gillette Children’s is an equal opportunity employer and will not discriminate against any employee or applicant for employment because of an individual’s race, color, creed, sex, religion, national origin, age, disability, marital status, familial status, genetic information, status with regard to government assistance, sexual orientation or gender identity, military status, or any other class protected by federal, state, or local law.

    Gillette Children’s is a global beacon of care for patients with brain, bone and movement disorders that begin in childhood. Our research, treatment and supportive technologies empower every child to live a full life defined by their dreams, not their diagnoses.

    For more information about working at Gillette Children’s, visit https://www.gillettechildrens.org/careers.

    Gillette Children’s participates in the U.S. Department of Homeland Security (DHS) E-Verify program, an Internet-based employment eligibility verification system administered by U.S. Citizenship and Immigration Services. If E-Verify cannot confirm that you are authorized to work, Gillette will provide you with written instructions and the option to contact DHS or the Social Security Administration (SSA) to resolve the issue before Gillette takes further action undertakes. For more information about e-verify, visit https://www.e-verify.gov/.

    Source link

  • Towards functionally individualised designed footwear recommendation for overuse injury prevention: a scoping review | BMC Sports Science, Medicine and Rehabilitation

    Towards functionally individualised designed footwear recommendation for overuse injury prevention: a scoping review | BMC Sports Science, Medicine and Rehabilitation

     

    Overview

    Running shoes are often characterised based on their cushioning and motion control functionality. Consequently, we have categorised the literature review results into these sections. We discuss additional FDF that did not fit into the first two sections in a subsequent part, followed by an upper construction segment. In each chapter, we introduce a brief description of the FDF. Next, we present the results of studies, taking covariates into account and analysing BRFs. We further discuss studies that investigated BRFs without considering covariates. Finally, we place our findings in the context of the FDF’s potential to minimise the development of running-related overuse injuries (RRI). We identified 107 articles that met our inclusion criteria (Fig. 4, Supplementary 3 Table 1-12). Most of these articles were published at the start of the twenty-first century and primarily featured data from male runners (Fig. 5). We acknowledge a data gap in running footwear research, which aligns with the female data gap in sport and exercise science [24].

    Fig. 4
    A Scatter plot of the included articles. Articles for each footwear design feature are separated by the number of articles considering covariates (y-axis) and running-related biomechanical risk factors (x-axis). If applicable, covariates for each footwear design feature are reported. According to a recent Delphi study, scatters are scaled to their importance [25]. Larger diameters represent a higher level of importance, and smaller diameters a lower level of importance. White scatters were not reported in the Delphi study and are not scaled
    Fig. 5
    The publication timeline of the included articles, separated by the different footwear design features. Each pie chart represents one study with the fraction of male (dark-grey) and female (light-grey) runners. Pie charts are scaled to the number of runners included in the study. Larger diameters indicate larger sample sizes, and smaller diameters indicate smaller sample sizes

    Cushioning systems

    Cushioned midsoles were one of the first FDF introduced to modern running shoes. They were developed to provide a protective layer, attenuate the shock caused by the collision of the foot with the ground, and reduce local plantar pressure peaks [26]. The cushioning characteristics are modified in the midsole through material and geometry changes.

    Midsole compression stiffness and hardness

    Midsole compression stiffness, also known as hardness, is a fundamental material property that measures the deformation caused by an area load. In the past, midsoles were constructed with uniformly distributed compression stiffness. However, they can now be tailored to individually cushioned midsoles with varying properties at different locations due to the viscoelastic properties of the material [27].

    Twelve of thirty-five articles identified through our literature search considered covariates when analysing the response to differently cushioned midsoles (Fig. 4, Supplementary Table 1). Malisoux et al. considered the runner’s body mass as a covariate [28]. Athletes reported fewer injuries when running in softer midsoles, and lighter runners in hard shoes showed a greater risk of developing an RRI than heavier runners. Three articles investigated the biomechanical response of midsoles with varying hardness during different running speeds. Nigg et al. found that the vertical GRF loading rate increases with speed independent of the cushioning variations, while another study showed unchanged GRF loading rates with footwear of varying cushioning at different speeds, and yet another study showed lower GRF loading rates in harder midsoles with no dependence on running speed [29,30,31]. Running distance or running duration has been considered by five studies [32,33,34,35,36]. None of the studies found significant footwear-by-time/distance interaction effects on vertical GRF loading rates, ground contact times, peak rearfoot eversion angles, and knee flexion angle at initial contact. One article considered the runner’s foot strike pattern as a covariate [37]. Rearfoot strikers reduced the vertical GRF loading rate in a neutrally cushioned shoe, and mid- and forefoot strikers reduced the vertical GRF loading rate in a minimal shoe [37]. We identified one study considering the stiffness of the running surface as a covariate [38]. However, no main and interaction effects were observed in ground contact time and knee flexion angle at touchdown. Another study analysed the effect of surface inclination and midsole cushioning [39]. The authors showed that vertical GRF loading rates are equal when running on different surfaces with either a neutral or a cushioned running shoe. Although studies have examined a variety of covariates, there is much conjecture in the literature regarding their influence on biomechanical measures related to RRI, and no conclusive evidence to suggest that any one covariate is more important than another.

    When considering the effects of midsole hardness on BRFs without considering covariates, five studies found reduced peak rearfoot eversion in harder midsoles than in softer midsoles [40,41,42,43,44]. However, four studies found unchanged peak rearfoot eversion angles when running in soft and hard midsoles [34, 45,46,47]. Four studies reported that different midsole hardness could not systematically affect the rearfoot eversion range of motion [40, 44, 45, 48]. In contrast, one study found a reduction in the rearfoot eversion range of motion in hard midsoles [47], and another study found that the range of motion of the rearfoot was lower when runners were running in softer midsoles [49]. Conflicting findings were also observed for the rearfoot inversion angle at initial ground contact. One study found a reduction in rearfoot inversion when running in soft midsoles [40], and others found reduced inversion angles when running in hard midsoles [40, 48]. Conflicting findings have also been reported for the vertical GRF loading rate. Some studies found an increased vertical GRF loading rate in more cushioned than less cushioned shoes [29, 34]. Other studies found no effects of cushioning [46, 50,51,52], while others found decreased vertical GRF loading rate in cushioned shoes [41]. Only a few studies were identified addressing the effects of different cushioning characteristics on BRFs at more proximal joints. One article’s qualitative data showed that the knee abduction angle during the stance phase was reduced when running in softer than harder midsoles [53]. In contrast, another study found lower peak knee abduction angles when the midsole was manufactured with harder material [47]. A study by Malisoux and colleagues found that both soft and hard midsoles did not change peak hip abduction angles and moments and peak hip internal rotation angles [45]. When considering ground contact time as BRF for PFPS, most studies found no effect of midsole cushioning [29, 36, 38, 45, 49, 51, 54,55,56]. Overall, studies analyzing BRFs without considering covariates, resulted in inconsistent and conflicting findings. Interestingly, the footwear comfort perception reported by participants tends to be higher in regions where softer material is allocated than in those with harder materials [42, 49, 57, 58].

    In summary, the current literature suggests that the midsole hardness can potentially reduce the overall injury risk when adjusted to the runner’s body mass. Reduction in vertical GRF loading rates and subsequent minimizing PF injury risk could be achieved by individualising midsole cushioning to the runner’s foot strike pattern. Specifically, rearfoot strikers might benefit from cushioned shoes, while fore- and midfoot strikers could find minimal shoes advantageous. The lower vertical GRF loading rates observed in neutral shoes compared to cushioned shoes when running downhill suggest that customised midsole cushioning tailored to a runner’s training terrain could benefit runners with a PF history. Based on the limited literature, surface stiffness, running distance, and fatigue might be less important when individualising midsole hardness. Harder midsoles can reduce BRFs associated with MTSS, TSF, AT (rearfoot eversion movement), and ITBS (ground contact times). Indications that different shoe cushioning may alter vertical GRF loading rates are contradictory, and BRFs at more proximal joints have not been well studied.

    Midsole geometry

    Running footwear is often designed with a height gradient from the heel to the forefoot. Running shoes are defined by their heel and forefoot heights, with the difference between the two known as the heel-toe drop. Unlike neutral or motion-control shoes, minimal footwear is typically designed with a lower heel-toe drop. An increase in footwear minimalism generally shifts the foot strike pattern of rearfoot strikers towards a mid- or forefoot strike pattern, and it is further assumed to reduce impact loading parameters [59, 60].

    We identified eighteen articles investigating the effects of geometrical midsole modifications matching our inclusion criteria (Fig. 4, Supplementary Table 2). Out of the eighteen articles, nine accounted for a covariate. The runner’s experience was considered in one article [61]. During a six-month follow-up, it was shown that occasional runners (< 6 months running experience) had reduced injury rates, and recreational runners (≥ 6 months running experience) had increased injury rates when running in footwear with lower heel-toe drop. A subset of this data demonstrated that midsoles with different heel-toe drops were not able to reduce peak rearfoot eversion angle and ground contact time [62]. However, runners who trained for six months in footwear with higher heel-toe drops increased the peak knee abduction angle. On the contrary, runners who trained for six months in footwear with lower heel-toe drops reduced the peak knee abduction angle. Running surface as a covariate was considered by one study [63]. The researchers found smaller knee flexion angles for larger heel-toe drops when running on a treadmill. However, when running overground, the knee flexion angle was not changed when running in shoes with different heel-toe drops. The authors found that increasing the heel-toe drop led to lower vertical GRF loading rates overground, but decreasing the heel-toe drop reduced vertical GRF loading rates during treadmill running. Different running speeds as a covariate were considered by four articles [64,65,66,67]. One study found no changes in the knee flexion angle at initial contact when running at different speeds in midsoles with different heel-toe drop designs [64]. Another study showed that while ground contact time decreased with increasing speed, increasing the heel-toe drop resulted in increased contact time [65]. Other researchers also showed similar results when systematically altering running speed and heel-toe drop [66]. Running speed did not influence the effects of heel-toe drop modifications on vertical GRF loading rates or time spent in rearfoot eversion [67]. The interaction effects of running time and geometrical midsole modifications were investigated in two studies using the same data set [68, 69]. However, neither of the studies reported interaction effects on included BRFs (rearfoot movement, contact time, and knee flexion angle at initial ground contact). Nevertheless, both studies reported longer ground contact times, lower rearfoot eversion range of motion, and greater knee flexion angles at initial contact in thicker than thinner midsoles.

    Concerning the general effects of midsole geometries on BRFs without considering covariates, most of the included studies have addressed the effect of midsole geometry on GRF parameters. An increase in heel-toe drop has been reported to reduce vertical GRF loading rates [70,71,72,73]. Diverse results have been reported for midsole thickness, for which one study found lower vertical GRF loading rates in thicker than thinner midsoles [74], whereas another study could not identify any differences [75]. Three studies showed that geometrical changes at the midsole do not affect rearfoot inversion at touchdown [68,69,70]. Three articles showed that the knee flexion angle at touchdown remains unchanged independent of geometrical midsole configurations [72, 75, 76]. Only one study collected comfort perception data from fifteen male runners [77]. However, no difference in comfort was observed when the heel-toe drop was systematically altered.

    Summarising the results, individualisation of heel-toe drop based on runner experience may reduce the risk of RRI. Although the underlying biomechanical mechanism remains unknown, a gradual transition from shoes with different heel-to-toe drops may allow adequate adaptation of the biological tissues. Running surfaces can affect the response to heel-toe drop alterations by influencing vertical GRF loading rates and knee flexion angles. Runners with a history of PF training on treadmills may benefit from shoes with a lower heel-toe drop, while those with a history of ITBS may benefit from a higher drop. During fatigue, geometric midsole modifications may not affect rearfoot eversion movement or ground contact times. Thinner midsoles with a lower heel-toe drop may reduce ground contact times, peak rearfoot eversion angle and rearfoot eversion duration. Hence, these modifications might be recommended for runners with a risk or a history of PFPS, TSF, or MTSS. Moreover, thicker midsoles with a higher heel-toe drop might shift BRFs related to AT and PF (rearfoot eversion range of motion and vertical GRF loading rate) to potentially less critical BRF magnitudes.

    Motion control features

    Motion control, also called stability, in footwear refers to how the shoe limits pronation (calcaneal eversion) or supination (calcaneal inversion) during the support phase. Much research has been devoted to FDF that purports to control pronation or eversion motion, motivated by the retrospective observations that increased pronation angle is associated with RRI [10, 78,79,80]. Over the initial period of footwear research, various midsole technologies were designed to increase rearfoot stability, including altering the midsole hardness, location of material inserts, flares, arch support systems, and postings. One of the few identified studies utilized a randomized controlled trial with a six-month follow-up. The findings revealed that recreational runners with a motion control shoe developed fewer RRI than runners receiving a standard running shoe [15]. Interestingly, motion-control shoes’ effectiveness in reducing RRI development was more pronounced for runners with pronated feet, indicating some potential for footwear individualisation.

    Postings

    Postings in athletic footwear incorporate elements with higher material densities in the medial rearfoot region and have been reported to limit rearfoot eversion [81]. Unlike wedges, postings are designed without gradual height differences [82].

    Three of seven articles identified through our literature search considered covariates in their analysis (Fig. 4, Supplementary Table 3). The runner’s age was considered by one article [83]. Medial posts effectively reduced the amount of rearfoot eversion in older compared to younger female runners, while vertical GRF loading rates, peak knee abduction moments, and peak knee internal rotation angles remained unchanged. When considering the runners’ fatigue as a covariate, two articles found that rearfoot eversion movement (peak and range of motion) was lower when running in a medially posted than in a neutral running shoe when the runner’s fatigue increased [84, 85].

    When not considering covariates or subgroups of runners, medial postings can reduce peak rearfoot eversion angles and eversion range of motion [86, 87]. Peak knee internal rotation angles are reported to be reduced when running in footwear with medial postings [83, 88]. However, footwear with postings might increase peak hip abduction moments [89]. Diverse results were found for vertical GRF loading rates. One study found lower vertical GRF loading rates in midsoles without medial posts [87], and another found unchanged vertical GRF loading rates in shoes with and without postings [83]. Some runners have perceived the harder posting material without transitions as uncomfortable, potentially resulting in unwanted changes in their biomechanics [88].

    In summary, older female runners with a history of TSF and MTSS might reduce rearfoot eversion in shoes with postings. However, medial posts do not seem to affect the risk of developing PF independent of the runners’ age since changes in vertical GRF loading rates were not observable. Based on the limited literature, posted midsoles may help minimise BRFs (rearfoot eversion movement) associated with AT, MTSS, or TSF as the runners’ fatigue state increases. The limited literature suggests that individualised postings can help runners with a history of AT, MTSS, TSF, or ITBS to reduce biomechanical risk factors. Since postings might increase vertical GRF loading rates, caution needs to be taken by runners with a history of PF.

    Wedges

    Wedges are sloped orthotic inserts, typically with mediolateral elevation, designed to increase foot stability. Mediolateral elevation under different loading conditions can be achieved by incorporating materials with different mechanical properties at distinguished locations of the wedge [90].

    Three out of the ten articles identified in the literature search included a covariate in their analysis (Fig. 4, Supplementary Table 4). One study considered running duration (0–30 min) as a covariate [91]. Independent of the running duration, medially wedged insoles produced lower knee abduction angular impulses than laterally wedged insoles. Another study considered different standing calcaneal angles and injury history as covariates [92]. However, wearing differently wedged insoles showed no effect on female runners’ 3D knee and hip kinematics. Anterior knee pain as a covariate and the response to differently wedged insoles were considered by one article [93]. Independent of knee pain, running in medially wedged insoles reduced maximal rearfoot eversion and range of motion compared to running in footwear without wedges. None of the studies personalised the wedges to the runner’s individual foot anatomy; instead, they used pre-fabricated wedges, which may have confounded these results.

    Seven articles were identified investigating the effect of wedged insoles on BRFs without considering covariates. In a study in which the wedges were customised to individual dynamic barefoot plantar pressure data, all but two subjects reduced peak rearfoot eversion angles compared to footwear without wedges [94]. This finding suggests that wedges bear high potential when individualised to foot pressure mapping. Pre-fabricated medial wedges have proven effective in decreasing maximal rearfoot eversion angles and eversion range of motion [94,95,96,97]. When comparing footwear with and without wedges, non-systematic changes in vertical GRF loading rates and knee abduction angular impulse have been reported [95, 96, 98, 94, 99, 100]. When the mediolateral elevation was systematically altered, no perceived comfort and stability changes were reported [95]. Moreover, neither medially nor laterally wedged insoles were able to relieve runners of patellofemoral pain [99]. One study introduced forefoot wedges with systematic changes in elevation; however, no changes in ground contact times were reported [101].

    In summary, the response to medially wedged insoles is independent for shorter running durations (< 30 min) but may help runners with a history of PFPS to minimise knee abduction angular impulses; however, the effect for longer running durations (> 30 min) remains unknown. The limited literature shows that joint alignments, injury history, and knee pain are less relevant covariates when individualising wedged insoles. Medially wedged insoles might sufficiently limit rearfoot eversion movement and support runners with a history of AT, TSF, and MTSS to reduce reinjury. To attenuate vertical GRF loading rates, runners with a history of PF might refer to other FDF modifications to reduce the overuse injury risk.

    Arch support systems

    Arch support systems help the foot by storing and releasing elastic energy and preventing arch collapse during high loading [102]. Foot arches can be classified as flat/low, normal, or high [103]. Within the three groups, low-arched runners may exhibit greater eversion movement and velocity than high-arched runners [104]. Arch support systems can be integrated into the midsole or achieved through custom-made insoles shaped into the foot arch [105].

    Our review found seven articles, four of which examined the effect of arch support systems on running biomechanics with a covariate (Fig. 4, Supplementary Table 5). Two studies used foot arch height as the covariate, and they found that high-arched runners reduced vertical GRF loading rates in a shoe without arch support, while low-arched runners reduced loading rates in a shoe with arch support. However, both foot arch types experienced reduced rearfoot eversion in a motion control shoe [106]. With a subset of this data, no changes in rearfoot eversion movements for runners with different foot arch types were observed when running in shoes with and without arch support systems during a prolonged run [107]. One article accounted for the runner’s foot strike pattern and found that rearfoot strikers decreased ground contact time in footwear without arch support [108]. In contrast, forefoot strikers reduced contact time in a shoe with arch support [108]. The same study found that forefoot strikers in minimal footwear reduced vertical GRF loading rates, but rearfoot strikers did not. Furthermore, training for three months in footwear with a custom-made arch support system reduced rearfoot eversion [105].

    We identified three articles investigating the effect of arch support systems on BRFs without considering covariates. A study involving female runners found no effect of arch support on vertical GRF loading rates, peak rearfoot eversion angles, and peak femur rotation angles [46]. Another study also found unchanged rearfoot eversion movements (peak eversion angle and rearfoot inversion at initial ground contact) and knee abduction angles when runners with AT symptoms ran in footwear with and without arch support [109]. Although BRFs were unchanged, a 92% relief of AT symptoms was reported when wearing an insole with custom-made arch support. Finally, one study found unchanged ground contact times when running in midsoles with 20 mm and 24 mm high arch support elevations [101].

    The limited literature suggests that arch support systems can potentially reduce BRFs for runners with different arch heights and a history of PF. Runner’s foot strike pattern might be considered when individualising arch support systems. When individualising arch support systems to minimise BRFs associated with PFPS (ground contact time) and PF (vertical GRF loading rate), forefoot strikers might benefit from less arch support than rearfoot strikers. Moreover, customised arch support systems enhance comfort perception without changes in peak knee abduction angles and vertical GRF loading rates. Arch support might reduce rearfoot eversion movements and thus have the potential for individualisation for runners with a history of AT, TSF, and MTSS. BRFs related to ITBS (peak femur rotation angle and peak knee abduction angles) seem to change marginally and unsystematically with arch support.

    Heel flares

    Flares can be described as a projection of the midsole and outsole extending beyond the upper [25]. Flares can be placed medially or laterally along the outline of the midsole and were introduced to alter the rearfoot eversion angle, thus increasing foot stability by changing the ankle joint moment arm [110,111,112].

    After examining all articles, we identified five matching our inclusion criteria (Fig. 4, Supplementary Table 6). None of these articles investigated the effect of a covariate.

    Concerning BRFs, one study altered the medial heel flare from 0° to 15°, and 30°. The 2D video-based analysis indicated higher rearfoot eversion movement in footwear without heel flares [81]. In the same study, runners running in shoes with the most extreme medial heel flare modification had, on average, lower rearfoot eversion range of motion than in shoes with less or without heel flares. These findings were supported by other research showing that footwear with heel flares can reduce the magnitude of rearfoot eversion across the entire stance phase but does not seem to reduce vertical GRF loading rates [110, 112, 113]. On the contrary, one study with only five runners did not show that rearfoot eversion movement (at initial ground contact, peak, and range of motion) changes when running in footwear with different heel flares [111]. From a perception perspective, heel flares can improve perceived foot stability [112].

    None of the articles considered covariates (e.g., foot strike pattern), highlighting future research potential. Although we found diverse results regarding rearfoot eversion movement, midsoles with heel flares might reduce BRFs linked to AT, TSF, or MTSS. Based on the very limited body of literature, midsoles with heel flares are insufficient for reducing vertical GRF loading rates, and individualised heel flares may not target runners with a history of PF.

    Crash pads

    Crash pads are elements incorporated into the posterior-lateral midsole using softer foams, segmented geometries, air pockets, or gel-filled patches. Crash pads in the rearfoot area aim to attenuate the GRF and reduce the GRF’s lever arm to the ankle joint [114].

    After assessing articles for their eligibility, we identified three articles matching our inclusion criteria (Fig. 4, Supplementary Table 7). Out of the three articles, one study considered the fatigue status of female runners as a covariate. As the runners’ fatigue increased, wearing footwear without crash pads increased vertical GRF loading rates compared to the non-fatigue state. However, running in footwear with crash pads maintained consistent vertical GRF loading rates, even as the runners’ fatigue increased. [115]. The same study found no effect of fatigue on the peak free moment amplitude.

    When not considering covariates, two studies found reduced rearfoot inversion angles at touchdown in footwear with smaller compared to larger crash pad dimensions. However, there were no differences in peak rearfoot eversion angles during the stance phase of running and unsystematic changes in vertical GRF loading rates [114, 116]. Crash pad modifications did not affect the peak free moment amplitude, ground contact time, and rearfoot eversion range of motion [114,115,116]. Changes in crash pad dimensions do not seem to influence the runner’s comfort perception [114]. However, they may provide an essential tool for individualisation to tune midsole cushioning properties without increasing stack height which has been shown to increase rearfoot eversion [81].

    Fatigue seems to be a relevant covariate when individualising crash pads to minimise vertical GRF loading rates, thus, might lower the risk of developing PF. However, runners with a history of TSF might need other individualised FDF to lower peak free moment amplitudes. Increasing crash pad height might help runners with plantar fascia complaints by lowering the vertical GRF loading rates. Runners with a history of AT, TSF, or MTSS might benefit from crash pads by reducing rearfoot eversion movement. Surprisingly, although the FDF aimed at attenuating the peak impulse, we have identified only two studies that have analysed vertical GRF loading rate as BRF.

    Other footwear design features

    Rocker

    Rockers in running shoes aim to reduce the strain on the toes, foot, and ankle by altering the midsole’s curvature in the anterior–posterior direction, positioning the apex near the metatarsal heads, and enhancing the midstance-to-push-off transition for a smoother heel-to-toe rolling motion [117].

    Each of the three identified articles considered a covariate in their analysis (Fig. 4, Supplementary Table 8). One study considered running speeds as a covariate. Although running at higher speeds increases the vertical GRF loading rate, no changes in GRF loading rates were observed between shoes with and without rocker [118]. Two studies considered the foot strike pattern and found that a toe spring starting closer to the midfoot reduced pressure in the forefoot compared to a standard rocker placed at 65% of the shoe length [119]. However, runners perceived the traditional rocker as more comfortable. When compared to shoes without rockers, one study found that a rocker shoe reduced ground contact time but did not affect knee flexion angles at initial ground contact [120].

    The number of studies addressing injury-specific BRFs and the effects of rocker designs is limited. Rockers involve different levels of FDF (stack height, cushioning), and therefore it is difficult to assign a specific feature to a specific BRF. More research is needed to understand if certain covariates can cause a specific change in BRFs and how different FDFs that combine a rocker design need to be tuned for individualisation.

    Outsole profile

    A shoe’s outsole interacts with the running surface and requires attributes like traction, waterproofness, durability, and puncture resistance [121]. Material robustness might be related to running shoe comfort, and high traction might increase free moment amplitudes associated with TSF [122].

    After assessing all articles for eligibility, we could not identify any articles matching our predefined inclusion criteria (Fig. 4). Future studies might use wearable sensors or markerless tracking systems to analyse runners wearing shoes with different outsole profiles on natural surfaces.

    Flex grooves

    Flex grooves and zones are included in outsoles and midsoles to enhance flexibility, facilitating metatarsophalangeal joint movement and shock absorption. Their placement is essential for the joint’s variable axis and should be individualised based on foot measurements. Recent 3D measurements indicate significant variation, underscoring the need for personalized flexible zones [123].

    Our literature search identified one article matching our predefined inclusion criteria (Fig. 4, Supplementary Table 9). This article considered running speed as a covariate. In this study, the midsole flexibility was altered by cuts with different orientations at the heel region. Although interaction effects were only marginal when jogging or running in footwear with different groove designs, a 10% lower vertical GRF loading rate was observed in the midsole with grooves compared to the midsoles without grooves at the rearfoot [124]. Interestingly, footwear with greater flexibility is perceived as more comfortable than midsoles with less flexibility [125, 126].

    While there is limited research on the impact of flex grooves on relevant BRFs for common RRI, one identified article found that they can reduce vertical GRF loading rates, suggesting that flex grooves may be customised for runners with PF.

    Longitudinal bending stiffness

    The longitudinal bending stiffness can impact the running economy by optimising energy return and kinematics of the metatarsal joint and force application [127,128,129,130,131]. The bending stiffness can be modified by adding reinforcement materials or changing the geometry of stiff midsole compounds. The optimal bending stiffness depends on factors such as running speed and body weight [128, 132].

    Our literature search identified eleven articles, of which four accounted for a covariate (Fig. 4, Supplementary Table 10). All four articles considered running speed as a covariate. None of these articles found a significant interaction effect on BRFs when running in footwear with different longitudinal bending stiffness at different running speeds [133,134,135,136]. Independent of running speed, studies reported reduced ground contact times when running in shoes with lower bending stiffness, while one article found unchanged ground contact times [136].

    When not considering covariates, three studies found no changes in the GRF braking impulse when running in shoes with different bending stiffness [135, 137, 138]. On the contrary, a reduction in GRF braking impulse in footwear with higher bending stiffness was found in one study [134]. Eight articles found a reduction in the ground contact time [130, 133,134,135, 137,138,139], and two found unchanged ground contact times [134, 140] when running in midsoles with lower bending stiffness. Although studies found lower vertical GRF loading rates [140] and increased comfort perception [135] when athletes ran in more flexible than stiffer midsoles, the relationship between BRFs and injury development when altering the longitudinal bending stiffness has not been sufficiently studied yet, but first studies have evolved showing that bones stress injuries might increase when switching to footwear with carbon fibre plates [18].

    The limited body of literature suggests that fitting longitudinal bending stiffness to the runner’s needs may help with treating PFPS. While reduced bending stiffness can reduce ground contact time, higher stiffness can reduce ground reaction force braking impulse. However, injury prevention and reinjury risk minimisation under the light of different longitudinal bending stiffness has been insufficiently investigated. Furthermore, flexible midsoles with lower longitudinal bending stiffness might reduce vertical GRF loading rates and potentially help runners with a history of PF.

    The upper

    The running shoe upper is comprised of a textile fabric and lacing system that couple the foot and shoe, with reinforcement materials used for stability and breathability. An optimal fit depends on individual foot morphology, while insufficient coupling can negate benefits from other design features. Moreover, excessive pressure can affect comfort by restricting blood supply, making individualisation important [141]. Since foot dimensions differ across sexes, ages, and ethnic origins, individualised upper bears great potential for individualisation [142].

    Upper fabric

    Our systematic literature search identified two articles investigating the effect of different upper modifications (Fig. 4, Supplementary Table 11). None of the articles considered covariates [53, 143].

    The data indicates that a soft-sewed structured fabric reduces knee abduction angles and vertical GRF loading rates compared to a minimalist heat fusion fabric. Furthermore, the ground contact time was reduced when running in minimalist heat fusion fabric.

    The current body of literature is insufficient to give recommendations for upper individualisation concerning the reduction of BRFs. Based on the limited results, upper materials might be individualised to the runner’s preference.

    Lacing

    Five articles have investigated the effect of lacing on the lower extremity joint biomechanics or subjective comfort perception (Fig. 4, Supplementary Table 12).

    One of five studies considered the runner’s experience as a covariate. The researchers found that low-level runners perceived an irregularly (skipping eyelets) laced running shoe as more stable and comfortable than high-level runners who preferred a regular high and tight lacing pattern [144].

    We identified four studies analysing BRFs without accounting for covariates. According to a study, running shoes with traditional lacing and elastic upper material were perceived as more comfortable than footwear without lacing [145]. When running in shoes with various lacings, two studies found no significant difference in the rearfoot eversion angle at initial contact [145, 146]. The same studies found a reduction in the peak rearfoot eversion angle when running in traditionally laced shoes compared to those without traditional lacing. However, another study systematically changed lacing patterns and could not find any differences in the peak rearfoot eversion angle [147]. Different types of lacing patterns, particularly high- and tightly-laced shoes, have been shown to reduce vertical GRF loading rate at the cost of comfort [144, 148].

    Studies analysing BRFs and considering relevant covariates, e.g., foot shape, are required in the future. Notably, no studies have measured the foot-shoe coupling or the relative movement of the foot within the shoe, highlighting the potential for future research to determine individualised fits and their interactions with other FDF. Since peak rearfoot eversion angles and vertical GRF loading rates are reported to be lower when running in tightly and high-laced shoes, runners with a history of MTSS and TSF might target individualised lacing systems.

    Source link

  • 2024-2025 Orthopedic Value-Based Healthcare Research Fellowship

     

    The Fellow will collaborate with department faculty on research projects related to the design, implementation and dissemination of value-based care models, outcome measurement (including the effect of interventions on patient-reported outcomes), costs of care, impact of psychosocial aspects in conditions to the musculoskeletal system, advances in shared decision-making and patient and caregiver engagement, and the adoption of digital health solutions.

    Faculty

    The Fellow will work directly with several leaders in healthcare innovation, including:

    • Kevin Bozic, MD, MBA, professor and chairman of the Department of Surgery and Perioperative Care
    • David Ring, MD, PhD, Associate Dean of Comprehensive Care; Professor of Surgery and Psychiatry
    • Karl Koenig, MD, MS, associate professor and executive director of the Musculoskeletal Institute
    • Prakash Jayakumar, MBBS, PhD, Assistant Professor and Director of Value-Based Healthcare and Outcomes Measurement

    Key Responsibilities and Fellowship Functions

    1. Research: Core research tasks include the development of research protocols, administration of Institutional Review Board (IRB) applications, patient recruitment in the Musculoskeletal Institute’s Lower Extremity Integrated Practice Unit (IPU), data collection and dissemination via abstracts, presentations and manuscripts for multiple publications. The Fellow will serve as a principal investigator in the lower extremity IPU (2.5 days/week) and supervise student and medical student volunteers in patient recruitment and data collection.
    2. Strategy and Operations: Gain valuable insights into the organization’s strategic planning and clinical/operational needs by attending business and management meetings and becoming involved in operational projects as necessary.
    3. Educational opportunities and networking
      1. Immersion program. The Fellow will participate in our quarterly Musculoskeletal Institute Immersion Program in Value-Based Health Care, which accommodates up to two dozen attendees, including a variety of leading stakeholders in orthopedics and beyond from across the country. The program provides comprehensive insight into our value-based model for musculoskeletal care delivery over two half days of presentations and interactive sessions and ample opportunity for networking and in-depth discussions.
      2. Value-based healthcare curriculum. Complete courses related to Value-Based Health Care through an executive education course from UT Austin’s Value Institute for Health and Care.
      3. AAOS Annual Meeting. The department will support the Fellow’s participation in the AAOS Annual Meeting.
      4. Grand rounds. The Fellow may attend Grand Rounds and other clinical conferences.
    4. Clinical: Exposure to clinical patient care and surgical practices by shadowing faculty in clinical activities (operating room, hospital, and outpatient clinic). Although the Fellow will be most integrated with our Musculoskeletal Institute team, opportunities exist for shadowing and research in other surgical specialties within the Department of Surgery and Perioperative Care, based on the Fellow’s interests. He/she will have ample opportunities to interact with orthopedic surgery residents, as well as other residents and students in the department and throughout Dell Medical School.

    A compensation

    Salary: $35,000 plus benefits. Read more about UT Austin’s employment benefits here.

    Eligibility

    Applicant must have been admitted or enrolled in medical school at the time of application.

    Required: strong critical thinking skills; very motivated; can work well independently and in a team; strong written/verbal communication and organizational skills; basic knowledge of statistics.

    Preferred: Demonstrated interest in value-based healthcare; experience in conducting research projects through publication; completion of core clinical internships (e.g., current third-year medical student); experience creating PowerPoint presentations; skills with data analysis; fluent in Spanish.

     

    Timeline

    The Fellowship runs from July 1, 2024 to June 30, 2025, although there is some flexibility in dates. The deadline for registration is January 15, 2024. Zoom interviews will be conducted with finalists and we plan to fill the position by March 1stst.

    How to apply

    Submit your resume (with USMLE Step 1 and Step 2 scores, if applicable), a one-page cover letter, and a list of three references via our Workday post. If available, include an example of previous work (PowerPoint presentations, published research, data analysis, etc.).

    If you have any questions about the position or the application process, please contact Lauren Uhler, MPH, Associate Director of Research, at This email address is being protected from spambots. You need JavaScript enabled to view it..

    Learn more

    For more information, visit our website https://dellmed.utexas.edu/education/academics/additional-training-programs/orthopaedic-value-based-health-care-fellowship

    Source link